Treatment of Hypertension With Ketanserin, a New Selective 5-Ht2 Receptor Antagonist.

BMJ

doi 10.1136/bmj.284.6315.537

Full Text

Abstract

Available in

Date

February 20, 1982

Authors

A J Man in 't Veld

Publisher

BMJ

Related search

Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in Essential Hypertension.

British Journal of Clinical Pharmacology

English

The Effects of a Selective 5-Ht2 Receptor Antagonist (ICI 170,809) on Platelet Aggregation and Pupillary Responses in Healthy Volunteers.

British Journal of Clinical Pharmacology

English

The 5-Ht2 Antagonist Ketanserin Is an Open Channel Blocker of Human Cardiac Ether-À-Go-Go-Related Gene (hERG) Potassium Channels

British Journal of Pharmacology

English

Robalzotan (NAD-299), a Novel Selective 5-Ht 1A Receptor Antagonist

CNS Drug Reviews

English

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension

Basic and Clinical Pharmacology and Toxicology

English

AE9C90CB: A Novel, Bladder-Selective Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder

British Journal of Pharmacology

English

New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)

Cardiovascular Medicine

English

5-Ht3 Receptor Antagonism by Anpirtoline, a Mixed 5-Ht1 Receptor Agonist/5-Ht3 Receptor Antagonist

British Journal of Pharmacology

English

5-Ht2 Receptor Binding, Functional Activity and Selectivity in N-Benzyltryptamines

Multidisciplinary

English